ARTICLE | Top Story
Immunocore, Genentech in cancer deal
June 28, 2013 1:17 AM UTC
Immunocore Ltd. (Abingdon, U.K.) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) partnered to use Immunocore's ImmTAC technology to discover and develop ImmTACs against multiple undisclosed cancer targets. An ImmTAC is a bi-specific molecule consisting of a soluble monoclonal T cell receptor (mTCR) fused to an anti-CD3 immunoglobulin fragment that recruits T cells to the tumor.
Genentech will have exclusive, worldwide rights to each ImmTAC program for all cancer indications. For each program, Immunocore will receive $10-$20 million in initiation fees and is eligible for more than $300 million in milestones, plus tiered royalties. ...